Nektar Therapeutics filed an 8-K on October 1, 2026, disclosing new Phase 2b data from REZOLVE-AA, its trial of rezpegaldesleukin (REZPEG, NKTR-358) in severe alopecia areata. The 92-patient study measured mean percentage reduction from baseline in scalp hair loss severity as its primary endpoint, and the data release came alongside a supplemental investor presentation. The filing does not detail the topline results, but the simultaneous press release and presentation suggest Nektar chose a coordinated data drop rather than a conference readout.
What makes REZPEG mechanistically distinct from the approved options is its target: regulatory T-cell stimulation rather than JAK inhibition. Baricitinib received FDA approval for severe alopecia areata in June 2022, with roughly one in three patients achieving meaningful hair coverage in pivotal trials. If REZPEG shows comparable response rates through a different pathway, it would give prescribers a non-JAK option for patients who don’t respond to or tolerate the approved agents. If the data are weaker, the case for advancing to Phase 3 becomes harder to construct given the existing competition.
The competitive backdrop is not static. Pfizer has run a Phase 2b/3 trial in alopecia areata with its oral JAK3 inhibitor PF-06651600, designed to enroll roughly 660 patients including adolescents down to age 12. Nektar’s 92-patient Phase 2b is a smaller, earlier read, meaning the dataset’s primary value is dose-selection and mechanistic signal, not a registration-ready result.
The number to watch from the full data release is the responder rate at the highest dose arm on the scalp severity scale. A double-digit separation from placebo would be enough to justify Phase 3 planning; anything softer puts the program in a difficult position in a field where at least one approved oral therapy already exists and a larger trial is already underway.
Source link: https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/ea0307306-8k_nektar.htm
rezpegaldesleukin: the facts in one place
- Also written: NKTR-358, REZPEG, LY3471851
- Sponsor: Nektar Therapeutics
- Mechanism: regulatory T-cell stimulator targeting the interleukin-2 receptor complex to preferentially stimulate regulatory T-cell proliferation and restore immune balance
- Indication studied: severe-to-very-severe alopecia areata
- Phase: Phase 2b
- Enrollment: 92
- Primary endpoint: mean percentage reduction from baseline in the Severity of Alopecia Tool (SALT) score at Week 36
- Headline result: 75% of patients maintained SALT Score ≤20 responses four months off treatment; 63% maintained this response at six months off treatment; 19% achieved SALT Score ≤10 at six months off treatment, up from 7% at Week 52
- Registry identifier: NCT06340360
- Current status: FDA Fast Track designation granted July 2025; Phase 3 ZENITH AA study planned to initiate in early 2027
- FDA Fast Track designation (severe alopecia areata): July 2025
- Phase 2b REZOLVE-AA data announced: October 1, 2026
- Phase 3 ZENITH AA study initiation planned: early 2027
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
